DENVER--(BUSINESS WIRE)--EvoEndo®, Inc. (EvoEndo) announces that the EvoEndo® Model LE Gastroscope is now FDA-cleared for patients of all ages — from neonates to adults. Since 2022, the EvoEndo System has been the only option available for sedation-free transnasal endoscopy for pediatric patients five and older. Now, the expanded indication makes safe, transoral endoscopy available to infants and young children, a previously underserved population. In just three years, EvoEndo has redefined what’s possible – and who it’s possible for.